Phase 1 clinical trial of CUDC-101 'throws kitchen sink' at head and neck cancer

(University of Colorado Denver) At 18 months median follow up, one patient's cancer had worsened, two had died, and nine remained free of disease. Testing of blood and tumor samples showed that CUDC-101 had indeed inhibited the action of EGFR, HDAC and Her2.